Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Procarbazine | |
| Synonyms |
N-4-isopropylcarbamoylbenzyl-N'-methylhydrazine Ibenzmethyzin N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]benzamide N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide PROCARBAZINE Benzethyzin Procarbazine Procarbazin procarbazine N-Methylhydrazine p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide |
|
| Definitions |
A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C62072 |
|
| ALT_DEFINITION |
The active ingredient in a drug that is used to treat advanced Hodgkin lymphoma and is being studied in the treatment of other types of cancer. Procarbazine blocks cells from making proteins and damages DNA. It may kill cancer cells. It is a type of antineoplastic agent and a type of alkylating agent.
|
|
| CAS_Registry |
671-16-9
|
|
| Chemical_Formula |
C12H19N3O
|
|
| code |
C62072
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C186328 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C186327 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C186341 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc PCDC
|
|
| DEFINITION |
A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.
|
|
| Display_Name |
Procarbazine
|
|
| FDA_UNII_Code |
35S93Y190K
|
|
| FULL_SYN |
N-4-isopropylcarbamoylbenzyl-N'-methylhydrazine Ibenzmethyzin N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]benzamide N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide PROCARBAZINE Benzethyzin Procarbazine Procarbazin procarbazine N-Methylhydrazine p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide
|
|
| Has_Salt_Form | ||
| Is_Value_For_GDC_Property | ||
| label |
Procarbazine
|
|
| Legacy Concept Name |
Procarbazine_Base
|
|
| Maps_To |
Procarbazine
|
|
| Preferred_Name |
Procarbazine
|
|
| prefixIRI |
Thesaurus:C62072
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance
|
|
| UMLS_CUI |
C0033223
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |